Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Return on Equity (2019 - 2025)

10x Genomics (TXG) has disclosed Return on Equity for 7 consecutive years, with 0.06% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 20.0% to 0.06% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.06% through Dec 2025, up 20.0% year-over-year, with the annual reading at 0.06% for FY2025, 19.0% up from the prior year.
  • Return on Equity hit 0.06% in Q4 2025 for 10x Genomics, up from 0.1% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.06% in Q4 2025 to a low of 0.71% in Q1 2021.
  • Historically, Return on Equity has averaged 0.27% across 5 years, with a median of 0.22% in 2025.
  • Biggest YoY gain for Return on Equity was 62bps in 2021; the steepest drop was -60bps in 2021.
  • Year by year, Return on Equity stood at 0.07% in 2021, then plummeted by -192bps to 0.21% in 2022, then crashed by -64bps to 0.34% in 2023, then rose by 26bps to 0.25% in 2024, then surged by 78bps to 0.06% in 2025.
  • Business Quant data shows Return on Equity for TXG at 0.06% in Q4 2025, 0.1% in Q3 2025, and 0.11% in Q2 2025.